As previously recommended in clinical trials, BC patients with positive ER status are usually treated with an ER inhibitor, such as tamoxifen (TAM), with positive outcome, while patients with negative ER status have a poor prognosis and a greater risk of being hormone-insensitive and immune to TAM (52). This evidence concerns the gene ESR1 and breast cancer.